Table 1: General characteristics of included studies.
Study |
Study design |
Mean Age (years) |
Country |
Prednisolone dose (mg/day)/duration (months) |
Intervention and Number of participants (n) |
Co-interventions and Number of participants (n) |
Duration of study (months) |
Outcomesa |
||
Denosumab |
comparison |
Denosumab |
comparison |
|||||||
Suzuki [28] |
Retrospective |
48 |
Japan |
5.1/38.6 |
- |
SC, 60 mg every 6 months (n = 48) |
- |
Denotas® chewable (n = 6) Eldecalcitol (n = 11) Alfacalcidol (n = 8) |
12 |
125 |
Iseri [32] |
Randomized controlled study |
66.3 |
Japan |
5/83 |
5/108 |
SC, 60 mg every 6 months (n = 14) |
Alendronate 35 mg/week (n = 14) |
Calcitriol (n = 1), Eldecalcitol (n = 10), Alfacalcidol n = 7) |
12 |
23457 |
Akashi [27] |
- |
64.19 |
Japan |
10.59/- |
- |
(n = 53) |
- |
- |
24 |
23 |
Dore [26] |
Randomized double-blinded placebo controlled |
55.5 |
USA |
5/≥ 3 |
5/≥ 3 |
SC, 60 mg (n = 28) or 180 mg (n = 33) every 6 months |
Placebo, SC (n = 29) |
Biphosphonates |
12 |
12567 |
Ishiguro [24] |
Prospective |
73.1 |
Japan |
8.68/41.4 |
- |
SC, 60 mg every 6 months (n = 36) |
- |
Denotas® (n = 36) |
28 |
1236 |
Sawamura [25] |
Prospective |
50.4 |
Japan |
7.4/208.8 |
- |
SC, 60 mg every 6 months (n = 29) |
- |
Alfacalcidol (n = 13) Eldecalcitol (n = 7) |
12 |
23567 |
Iwamoto [29] |
Retrospective |
63.4 |
Japan |
5.92/139.2 |
- |
SC, 60 mg every 6 months (n = 66) |
- |
Vitamin D and calcium (n = 15) Active vitamin D (n = 51) |
12 |
2567 |
Saag [31] |
Multicenter Randomized double-blinded active controlled |
63.7 |
USA Netherlands Canada Argentina France
|
14.45/- |
13.35/- |
SC, 60 mg every 6 months and placebo to risedronate orally once a day for 24 months. (n = 398) |
Risedronate oral 5 mg daily and placebo to denosumab by subcutaneous injection every 6 months (n = 397) |
1000 mg calcium 800 IU vitamin D |
24 |
123567 |
Kadoba [33] |
Retrospective |
67 (median age) |
Japan |
≥ 0.8 perkg/- |
≥ 0.8 perkg/- |
(n = 16) |
Bisphosphonates (n = 56) |
- |
30.5 |
67 |
Tanaka [34] |
Longitudinal cohort |
65 |
Japan |
6.2/- |
6.2/- |
(n = 60) |
Bisphosphonates (n = 150) |
- |
12 |
6 |
Yoshi [30] |
- |
71.9 |
Japan |
3.49/51.9 |
5.49/84.7 |
(n = 21) |
Bisphosphonates (n = 24), no drugs administered (n = 48) |
- |
12 |
238 |
Mok [35] |
Randomized, open, active controlled |
54.7 |
Hong Kong |
4.6/108.2 |
4.12/94.1 |
SC, 60 mg every 6 months (n = 21) |
Bisphosphonates (n = 21) |
Elemental calcium (n = 42) Calcitriol (n = 42) |
12 |
123567 |
a1-change in total hip BMD, 2-change in lumbar spine BMD, 3-change in femoral neck BMD,4-change in distal radius BMD,5-change in bone turnover markers, 6-fracture risk, 7-adverse events, 8-change in greater trochanter BMD